HHS Logo [ [link removed] ]

Blue Gradient


Change in Preferred Drug List Status for Drug Classes Takes Effect Oct. 16, 2023

In response to the shortage of the preferred brand name products Androgel, Norditropin, Genotropin, and Valcyte solution, the Texas Health and Human Services Commission has removed the non-preferred status [ [link removed] ] from the generic testosterone gel products and generic valganciclovir solution as well as the Omnitrope vial and Skytrofa on the preferred drug list (PDL).

*Other News*

* Synagis Prior Authorization Begins For All Health Service Regions [ [link removed] ]
* Vendor Drug Program Systems Changing Next Year [ [link removed] ]

*Reminders*

* Texas Drug Utilization Review Board Announces Vacancies [ [link removed] ]
* Pharmacy Education Information and Opportunities [ [link removed] ]
* Pharmacy Email Addresses Must Be Current in PEMS [ [link removed] ]








________________________________________________________________________

You have subscribed to get updates about Texas Health and Human Services (HHS). For more information about HHS, please visit our website [ [link removed] ].

________________________________________________________________________

Stay Connected Visit us on Facebook [ [link removed] ] Visit us on YouTube [ [link removed] ] Visit us on Twitter [ [link removed] ] Visit us on Instagram [ [link removed] ] Visit us on Facebook [ [link removed] ]  (en español)  

Bookmark and Share [ [link removed] ]

Subscriber Services
Manage Preferences [ [link removed] ]  |  Unsubscribe [ [link removed] ]  |  Help [ [link removed] ]

________________________________________________________________________

This email was sent to [email protected] using govDelivery Communications Cloud on behalf of: Texas Health and Human Services Commission · 707 17th St, Suite 4000 · Denver, CO 80202 GovDelivery logo [ [link removed] ]